Chimeric Therapeutics, is developing new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy against solid tumours.
Chimeric Therapeutics is jointly established by The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK. The company is aimed at translating an academic discovery programme funded by Cancer Research UK and developed by Dr Steven Lee and Prof Roy Bicknell at the University of Birmingham into a commercially viable cell therapy.